open access

Vol 11, No 6 (2010): Practical Diabetology
Review articles (submitted)
Published online: 2011-02-16
Get Citation

How to avoid oncogenic effects of insulin

Mariusz Jasik
Diabetologia Praktyczna 2010;11(6):197-203.

open access

Vol 11, No 6 (2010): Practical Diabetology
Review articles (submitted)
Published online: 2011-02-16

Abstract

The new reports suggests possible linking between diabetes and cancer incidence and diabetes treatments influence the risk of cancer. The excess risk of some cancers (liver, pancreas, endometrium, colon, breast, bladder) is associated with diabetes itself, what suggesting that the cancer could cause the diabetes, though usually men with diabetes have a reduced risk of prostate cancer. Diabetes and cancer are common diseases but potential links are considerably difficult. Possible mechanisms the relationship between diabetes and cancer include among others hyperglycemia, hyperinsulinemia and inflammation. Growth of cancer is caused by defective expression and function of the insulin and insulin- -like growth factors-I receptors and is promoted by insulin interacting with receptors. Appropriate diet, physical activity and reduction of body weight management reduce cancer risk in diabetes. Pharmacotherapy in diabetes is associated with an increased or reduced risk of cancer. Early evidence suggests that metformin is associated with a protective effect and considerable lower risk of cancer, while different other diabetes therapy options may promote tumour growth. Further new research will clarify how to avoid cancer in diabetes and oncogenic effects of insulin during the treatment of diabetes. (Diabet. Prakt. 2010; 11, 6: 197–203)

Abstract

The new reports suggests possible linking between diabetes and cancer incidence and diabetes treatments influence the risk of cancer. The excess risk of some cancers (liver, pancreas, endometrium, colon, breast, bladder) is associated with diabetes itself, what suggesting that the cancer could cause the diabetes, though usually men with diabetes have a reduced risk of prostate cancer. Diabetes and cancer are common diseases but potential links are considerably difficult. Possible mechanisms the relationship between diabetes and cancer include among others hyperglycemia, hyperinsulinemia and inflammation. Growth of cancer is caused by defective expression and function of the insulin and insulin- -like growth factors-I receptors and is promoted by insulin interacting with receptors. Appropriate diet, physical activity and reduction of body weight management reduce cancer risk in diabetes. Pharmacotherapy in diabetes is associated with an increased or reduced risk of cancer. Early evidence suggests that metformin is associated with a protective effect and considerable lower risk of cancer, while different other diabetes therapy options may promote tumour growth. Further new research will clarify how to avoid cancer in diabetes and oncogenic effects of insulin during the treatment of diabetes. (Diabet. Prakt. 2010; 11, 6: 197–203)
Get Citation

Keywords

oncogenic effects; insulin; pharmacologic therapy; diabetes

About this article
Title

How to avoid oncogenic effects of insulin

Journal

Clinical Diabetology

Issue

Vol 11, No 6 (2010): Practical Diabetology

Pages

197-203

Published online

2011-02-16

Bibliographic record

Diabetologia Praktyczna 2010;11(6):197-203.

Keywords

oncogenic effects
insulin
pharmacologic therapy
diabetes

Authors

Mariusz Jasik

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Diabetologia Kliniczna dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl